Clinical utility of a novel non-invasive technology for monitoring severe neutropenia in anticancer therapy.Manuel Alva Bianchi, Branko Cuglievan, Ephraim P. Hochberg et al.|Journal of Clinical Oncology|2023Cited by 1
13P HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): Implications for treatment stratificationRodrigo Sánchez-Bayona, Eva Ciruelos, O. Martínez-Sáez et al.|ESMO Open|2024Cited by 1
Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast CancerLola R. Nogueira, Rodrigo Sánchez-Bayona, Ana Maderuelo et al.|International Journal of Molecular Sciences|2026Cited by 1
Luminal breast cancer treatment beyond cell cycle inhibitorsRodrigo Sánchez-Bayona, Manuel Alva Bianchi|Revisiones en cáncer|2023Cited by 0
632eP Prevalence of ESR1 mutations in ER+/HER2- advanced breast cancer (aBC) patients treated with everolimus after CDK4/6 inhibitorsFrançois C. Bocquet, Alice Rudolph, M. Campone et al.|Annals of Oncology|2025Cited by 0